Edition:
India

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,137.00DKK
18 Jan 2018
Change (% chg)

kr.-18.50 (-1.60%)
Prev Close
kr.1,155.50
Open
kr.1,159.00
Day's High
kr.1,160.00
Day's Low
kr.1,132.50
Volume
283,638
Avg. Vol
301,947
52-wk High
kr.1,489.00
52-wk Low
kr.1,015.00

Latest Key Developments (Source: Significant Developments)

Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights
Wednesday, 10 Jan 2018 

Jan 9 (Reuters) - Genmab A/S ::GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO.MAJOR SHAREHOLDER ANNOUNCEMENT.  Full Article

Biotech Genmab sees 2018 expense growth of 40-50 pct
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA: :DENMARK'S GENMAB SEES 2018 EXPENSE GROWTH OF 40-50 PERCENT DRIVEN BY PIPELINE INVESTMENTS.SAYS ROYALTY FUNDS 100 PCT OF EXPENSE INVESTMENT.GENMAB TO CONDUCT NEW AND LARGER TISOTUMAB VEDOTIN TRIALS IN 2018.SAYS 6 PRE-CLINICAL PRODUCTS RAPIDLY ADVANCING.SAYS 2018 WILL BE 6TH YEAR OF PROFITABILITY.  Full Article

Genmab Achieves $20 Million Milestone In Daratumumab Collaboration With Janssen
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Genmab A/S ::GENMAB ACHIEVES USD 20 MILLION MILESTONE IN DARATUMUMAB COLLABORATION WITH JANSSEN AND UPDATES FINANCIAL GUIDANCE.GENMAB - EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2,240 - 2,440 MILLION.GENMAB - PAYMENT RELATES TO PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB & DEXAMETHASONE IN AMYLOIDOSIS.  Full Article

Genmab: $50 mln milestone payment in collaboration on Darzalex
Friday, 17 Nov 2017 

Nov 17(Reuters) - GENMAB A/S : :SAID ON FRIDAY WILL RECEIVE MILESTONE PAYMENT OF USD 50 MILLION IN DARZALEX COLLABORATION WITH JANSSEN BIOTECH, INC..SAID MILESTONE TRIGGERED BY SALES OF DARZALEX REACHING USD 1 BILLION IN A CALENDAR YEAR.THE MILESTONE WAS INCLUDED IN GENMAB’S 2017 FINANCIAL GUIDANCE PUBLISHED ON NOVEMBER 14, 2017.  Full Article

‍Genmab says expect 2017 revenue to be in range of DKK 2,110 – 2,310 mln
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Genmab ::‍GENMAB ACHIEVES USD 25 MILLION MILESTONE FOR FIRST COMMERCIAL SALE OF DARZALEX® (DARATUMUMAB) IN JAPAN AND UPDATES FINANCIAL GUIDANCE​.GENMAB SAYS ‍EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2.110 - 2.310 MILLION​.GENMAB-EXPECT DARZALEX ROYALTIES TO REMAIN IN RANGE OF DKK 930 - 1,100 MILLION WHICH ARE BASED ON ESTIMATED USD 1,100 - 1,300 MILLION OF DARZALEX SALES IN 2017​.‍NOW EXPECT OPERATING INCOME FOR 2017 TO BE APPROXIMATELY DKK 1,060 - 1,260 MILLION, COMPARED TO DKK 900 - 1,100 MILLION IN PREVIOUS GUIDANCE​.  Full Article

Genmab Q3 net loss DKK 5.7 mln, misses estimates
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - GENMAB A/S ::GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2017 <<>>.‍REVENUE WAS DKK 1,348 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 889 MILLION IN FIRST NINE MONTHS OF 2016​.‍OPERATING INCOME WAS DKK 641 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 345 MILLION IN FIRST NINE MONTHS OF 2016​.‍IS MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017 AND REITERATED ON SEPTEMBER 27, 2017​.Q3 REVENUE DKK ‍​ 323.4 MILLION (REUTERS POLL DKK 333 MILLION).Q3 OPERATING RESULT DKK ‍​ 58.3 MILLION (REUTERS POLL DKK 59 MILLION).Q3 NET LOSS DKK ‍​5.7 MILLION (REUTERS POLL PROFIT DKK 67.3 MILLION).  Full Article

Genmab: ‍worldwide net sales of darzalex $317 mln in Q3
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - GENMAB A/S :GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2017.‍WORLDWIDE NET SALES OF DARZALEX (DARATUMUMAB) AS REPORTED BY JOHNSON & JOHNSON WERE USD 317 MILLION IN Q3 OF 2017​.‍GENMAB WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC.​.  Full Article

Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Genmab A/S :Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer.Genmab - ‍companies plan to start enrolling patients by first half of 2018​.Genmab - ‍co, Seattle Genetics to start phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer​.  Full Article

Genmab says U.S. FDA grants priority review for daratumumab in relapsed multiple myeloma
Saturday, 8 Oct 2016 

Genmab : u.s. Fda grants priority review for daratumumab in relapsed multiple myeloma . Sbla was submitted by genmab's licensing partner, janssen biotech, inc. In august 2016 . Pdufa date set at june 17, 2017 . Fda has assigned pdufa target date of february 17, 2017 to take a decision on daratumumab . Fda has assigned a prescription drug user fee act (pdufa) target date of february 17, 2017 . Sbla submission also included data from phase i study of daratumumab in combination with pomalidomide and dexamethasone .Pdufa date for combination of daratumumab with pomalidomide/dexamethasone is june 17, 2017.  Full Article

Genmab: FDA approves Arzerra for treatment of relapsed chronic lymphocytic leukemia
Wednesday, 31 Aug 2016 

Genmab A/S :FDA approved a supplemental biologics license application for use of ofatumumab ((Arzerra) in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia.  Full Article

BRIEF-Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights

* GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO